Literature DB >> 26150053

Dyslipidemia and Diabetic Macular Edema: A Systematic Review and Meta-Analysis.

Radha Das1, Rebecca Kerr1, Usha Chakravarthy1, Ruth E Hogg2.   

Abstract

TOPIC: A systematic review and meta-analysis of dyslipidemia and diabetic macular edema (DME). CLINICAL RELEVANCE: Diabetic macular edema causes impairment of vision in patients with diabetes, and dyslipidemia has been reported as a risk factor for its development. A systematic review with a meta-analysis was undertaken to examine the evidence of an association between dyslipidemia and DME.
METHODS: We defined eligibility criteria as randomized controlled trials (RCTs) and cohort, case-control, and cross-sectional studies reporting on the relationship between blood lipid levels and DME. We performed a literature search in MEDLINE, PubMed, and Embase from inception to September 2014. We used the Newcastle-Ottawa scale to assess the quality of case-control, cross-sectional, and cohort studies, and the Cochrane risk of bias tool for RCTs.
RESULTS: The search strategy identified 4959 publications. After screening, we selected 21 articles for review (5 cross-sectional, 5 cohort, 7 case-control, and 4 RCTs). Meta-analysis of case-control studies revealed that mean levels of total serum cholesterol (TC), low-density lipoproteins (LDLs), and serum triglycerides (TGs) were significantly higher in patients with DME compared with those without DME (TC: 30.08; 95% confidence interval [CI], 21.14-39.02; P < 0.001; LDL: 18.62; 95% CI, 5.80-31.43; P < 0.05; TG: 24.82; 95% CI, 9.21-40.42; P < 0.05). Meta-analysis of RCTs did not show significant risk in worsening of hard exudates and severity of DME in the lipid-lowering group compared with placebo (hard exudates: relative risk, 1.00; 95% CI, 0.47-2.11; P = 1.00; DME: relative risk, 1.18; 95% CI, 0.75-1.86; P = 0.48).
CONCLUSIONS: Despite evidence from the cohort studies and meta-analysis of the case-control studies suggesting a strong relationship between lipid levels and DME, this was not confirmed by the meta-analysis that included only prospective RCTs. Therefore, given the significant public health relevance of the topic, the relationship between lipid levels and DME deserves further investigation.
Copyright © 2015 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26150053     DOI: 10.1016/j.ophtha.2015.05.011

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  28 in total

Review 1.  Diabetic macular oedema: pathophysiology, management challenges and treatment resistance.

Authors:  Bobak Bahrami; Meidong Zhu; Thomas Hong; Andrew Chang
Journal:  Diabetologia       Date:  2016-05-14       Impact factor: 10.122

2.  Nomogram-based prediction of clinically significant macular edema in diabetes mellitus patients.

Authors:  Zijing Li; Xiaowen Deng; Lijun Zhou; Tu Lu; Yuqing Lan; Chenjin Jin
Journal:  Acta Diabetol       Date:  2022-06-24       Impact factor: 4.087

Review 3.  Management of diabetic macular edema in Japan: a review and expert opinion.

Authors:  Hiroko Terasaki; Yuichiro Ogura; Shigehiko Kitano; Taiji Sakamoto; Toshinori Murata; Akito Hirakata; Tatsuro Ishibashi
Journal:  Jpn J Ophthalmol       Date:  2017-12-05       Impact factor: 2.447

4.  Effects of lipid-lowering agents on diabetic retinopathy: a Meta-analysis and systematic review.

Authors:  Rui Shi; Lei Zhao; Feng Wang; Fen Liu; Zhuo Chen; Rong Li; Yang Liu; Rong Lin
Journal:  Int J Ophthalmol       Date:  2018-02-18       Impact factor: 1.779

5.  Prevalence of referable, sight-threatening retinopathy in type 1 diabetes and its relationship to diabetes duration and systemic risk factors.

Authors:  A N Warwick; A P Brooks; C Osmond; R Krishnan
Journal:  Eye (Lond)       Date:  2017-01-27       Impact factor: 3.775

6.  Central Macular Thickness in Diabetic Macular Edema.

Authors:  H Gungel; H Aral; F Erdenen; M Gokce; S K Erdur
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Oct-Dec       Impact factor: 0.877

7.  Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy.

Authors:  Yoo-Ri Chung; Sung Wook Park; Shin-Young Choi; Seung Woo Kim; Ka Young Moon; Jeong Hun Kim; Kihwang Lee
Journal:  Cardiovasc Diabetol       Date:  2017-01-07       Impact factor: 9.951

8.  Genetically Determined Plasma Lipid Levels and Risk of Diabetic Retinopathy: A Mendelian Randomization Study.

Authors:  Lucia Sobrin; Yong He Chong; Qiao Fan; Alfred Gan; Lynn K Stanwyck; Georgia Kaidonis; Jamie E Craig; Jihye Kim; Wen-Ling Liao; Yu-Chuen Huang; Wen-Jane Lee; Yi-Jen Hung; Xiuqing Guo; Yang Hai; Eli Ipp; Samuela Pollack; Heather Hancock; Alkes Price; Alan Penman; Paul Mitchell; Gerald Liew; Albert V Smith; Vilmundur Gudnason; Gavin Tan; Barbara E K Klein; Jane Kuo; Xiaohui Li; Mark W Christiansen; Bruce M Psaty; Kevin Sandow; Richard A Jensen; Ronald Klein; Mary Frances Cotch; Jie Jin Wang; Yucheng Jia; Ching J Chen; Yii-Der Ida Chen; Jerome I Rotter; Fuu-Jen Tsai; Craig L Hanis; Kathryn P Burdon; Tien Yin Wong; Ching-Yu Cheng
Journal:  Diabetes       Date:  2017-09-26       Impact factor: 9.461

Review 9.  Does tight control of systemic factors help in the management of diabetic retinopathy?

Authors:  Ramachandran Rajalakshmi; Vijayaraghavan Prathiba; Viswanathan Mohan
Journal:  Indian J Ophthalmol       Date:  2016-01       Impact factor: 1.848

Review 10.  Eye disease and mortality, cognition, disease, and modifiable risk factors: an umbrella review of meta-analyses of observational studies.

Authors:  Mike Trott; Lee Smith; Nicola Veronese; Damiano Pizzol; Yvonne Barnett; Trish Gorely; Shahina Pardhan
Journal:  Eye (Lond)       Date:  2021-07-16       Impact factor: 4.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.